The Economic Impact of Clinical Pharmacist Involvement in the Public Procurement for Medicines and in the Drug and Therapeutics Committee

Bjelovar General Hospital

Status

Completed

Conditions

Rationalization

Treatments

Drug: Drug and Therapeutics Committee

Drug: Public procurement

Study type

Observational

Funder types

Other

Identifiers

NCT04314336

1520192020

Details and patient eligibility

About

The investigators have performed cost-minimisation analysis and compared the expenses based on the plan for public procurement (without clinical pharmacist involvement) for drugs with the results of public procurement based on the revised plan for public procurement by the clinical pharmacist. The plan for public procurements was based on the 1 year quantity for each medicine used by the hospital in the previous year, based on the latest deliverable prices at the time of extracting the data to workbook for MS Excel program (ver. 2002, Microsoft, Redmond, WA, USA).

The investigators have performed cost-minimisation analysis and compared the expenses for all received requests for medicines to the drug and therapeutics committee (DTC) for a decision in the 1 year period, before and after involvement of clinical pharmacist in the committee work. The expenses were based on approval decisions in the 1 year period for approval time period. The denial decisions were also calculated and reported. The denial period calculated in rationalisation of expenses were based on 1 year treatment period.

Enrollment

10,000 patients

Sex

All

Ages

1 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria